Indications
Therapeutic Asset Ratings
6,299 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Eb-Dnk101 Dual-Targeting Car-Nk Cells
Pancreatic Ductal Adenocarcinoma
Beijing Biotech
P1/2
CC
(44)
Eb-Nk-301
Cancer
Beijing Biotech
P1/2
CC
(44)
ect204 t cells
Hepatocellular Carcinoma
Eureka Therapeutics Inc.
P1/2
CC
(44)
Elranatamab
Hematopoietic And Lymphoid System Neoplasm
CellCentric Ltd.
P1/2
CC
(44)
Enzalutamide
Endometrial Carcinoma
Cancer Research UK
P1/2
CC
(44)
Epcoritamab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Yazeed Sawalha
P1/2
CC
(44)
Eras-007
Colorectal Cancer
Erasca, Inc.
P1/2
CC
(44)
Fruquintinib
Hodgkins Lymphoma
Immunitas Therapeutics
P1/2
CC
(44)
Gedatolisib
Prostate Disorder
Celcuity Inc
P1/2
CC
(44)
Gilteritinib
Plasma Cell Myeloma
Sumitomo Pharma America, Inc.
P1/2
CC
(44)
Gns 561
Hepatocellular Carcinoma
Genoscience Pharma
P1/2
CC
(44)
gt201
Neoplasm
RenJi Hospital
P1/2
CC
(44)
hcb101
Colorectal Cancer
Chang Gung Memorial Hospital
P1/2
CC
(44)
Humanized Monoclonal Anti-Fgfr1 Antibody Om-Rca-01
Renal Cell Carcinoma
Kidney Cancer Research Bureau
P1/2
CC
(44)
Hypoestoxide
Parkinson Disease
University of Ibadan
P1/2
CC
(44)
Iadademstat
Lung Cancer
National Cancer Institute (NCI)
P1/2
CC
(44)
Icasp9M28Z T Cell Infusions
Metastatic Neoplasm
Memorial Sloan Kettering Cancer Center
P1/2
CC
(44)
Ifebemtinib
Pancreatic Ductal Adenocarcinoma
InxMed (Shanghai) Co., Ltd.
P1/2
CC
(44)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer
Triple-Negative Breast Carcinoma
Cantargia AB
P1/2
CC
(44)
Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
Large Cell Neuroendocrine Carcinoma
Phanes Therapeutics
P1/2
CC
(44)
Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
Prostate Neuroendocrine Neoplasm
Phanes Therapeutics
P1/2
CC
(44)
Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
Small Cell Lung Carcinoma
Phanes Therapeutics
P1/2
CC
(44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Prostate Carcinoma
National Cancer Institute (NCI)
P1/2
CC
(44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Germ Cell Tumor
National Cancer Institute (NCI)
P1/2
CC
(44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Melanoma
National Cancer Institute (NCI)
P1/2
CC
(44)
Showing 4001 to 4025 of 6,299 assets
Previous
Page 161 of 252
Next